Login / Signup

Emerging therapies for overactive bladder: preclinical, phase I and phase II studies.

Samantha GibsonPamela Ellsworth
Published in: Expert opinion on investigational drugs (2024)
Current therapies for overactive bladder have limitations in efficacy and side effects. A greater understanding of the pathophysiology of overactive bladder has identified the role(s) of other pathways in the overactive bladder syndrome. Targeting alternative pathways including ion channels and enzymes may provide alternative therapies of overactive bladder and a more tailored approach to the management of overactive bladder.
Keyphrases
  • phase ii
  • clinical trial
  • open label
  • cancer therapy
  • randomized controlled trial
  • smoking cessation
  • case report
  • drug delivery
  • phase iii
  • cell therapy
  • case control
  • bone marrow